Region-Specific Enhancement of c-fos Expression by Combined Treatment With NMDA Receptor Agonists and Antagonists With Antidepressant Potential
Articolo
Data di Pubblicazione:
2022
Citazione:
Region-Specific Enhancement of c-fos Expression by Combined Treatment With NMDA Receptor Agonists and Antagonists With Antidepressant Potential / A. Vasilescu, N. Pfeiffer, F. Terraneo, M.A. Riva, U.E. Lang, D. Inta, P. Gass. - In: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. - ISSN 1461-1457. - 25:11(2022 Nov 17), pp. 946-950. [10.1093/ijnp/pyac051]
Abstract:
Rapastinel, formerly Glyx-13, is a novel positive allosteric modulator of the N-methyl-D-aspartate-receptor (NMDAR) that counteracts psychotomimetic actions of NMDAR antagonists. We set out to evaluate the effect of rapastinel alone or in combination with the global and GluN2B subunit-specific NMDAR antagonists MK-801 and Ro25-6981, respectively, on neuronal activation in relevant regions using c-fos brain mapping. Whereas rapastinel alone did not trigger significant c-fos expression beyond the prelimbic cortex, it strongly increased the c-fos expression induced by MK-801 in hippocampal, cingulate, and retrosplenial areas. Similar results were obtained when rapastinel was replaced by D-cycloserine. Our results reveal new interactions at network level between NMDAR modulators with possible implications regarding their therapeutic effects.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
D-Cycloserine; MK-801; NMDA receptors; Rapastinel; antidepressant drug
Elenco autori:
A. Vasilescu, N. Pfeiffer, F. Terraneo, M.A. Riva, U.E. Lang, D. Inta, P. Gass
Link alla scheda completa:
Link al Full Text: